
Introduction: Di-2-ethylhexyl phthalate (DEHP), a chemical used in medical bags and tubing, can leach into the bloodstream and bone marrow, causing oxidative stress in bone marrow mesenchymal stem cells (BMSCs). This study investigates the potential of gallic acid (GA), a potent antioxidant, to counteract DEHP-induced oxidative effects in vitro. Methods: BMSCs were exposed to various GA concentrations (0.063, 0.125, 0.25, 1, and 10 & micro;M) for 4 days, identifying 0.25 & micro;M GA as the optimal concentration based on cell viability. Cells were then treated with 100 and 500 & micro;M DEHP, with orwithout 0.25 & micro;M GA, for 4 or 8 days to assess viability, population doubling number, total protein levels, malondialdehyde levels, total antioxidant capacity, catalase and superoxide dismutase activity, cellular morphology, and expression of Nrf2 and NF kappa B genes. Results: Treatment with DEHP led to a significant, dose-and time-dependent reduction in viability, proliferation rate, total protein levels, total antioxidant capacity, and the activity of antioxidant enzymes. In contrast, GA treatment significantly increased these parameters. Additionally, DEHP resulted in an increase in malondialdehyde levels and caused morphological changes as well as down-regulated NF kappa B and up-regulating Nrf2 expression. In the co-treatment group, GA counteracted the toxic effects of DEHP at 100 & micro;M compared with control, whereas it only partially mitigated the toxic effects at 500 & micro;M. Conclusion: Consuming low concentrations of GA over time may reduce DEHP-induced oxidative stress. Further animal studies with GA-rich foods are essential to confirm its preventive benefits in vivo.
Introduction: In the realm of nerve injury repair, acellularized nerve grafts (ANGs) are gaining recognition as a promising tissue engineering approach, offering better regeneration outcomes compared to traditional nerve conduits. This study, conducted on rat and chicken sciatic nerves (R-ANGs and C-ANGs, respectively), seeks to explore an optimized nerve decellularization technique that achieves effective decellularization while preserving the extracellular matrix (ECM) integrity. Methods: The Sondell decellularization (SD) protocol was evaluated against an optimized Sondell decellularization (OSD) method improved by DNase treatment and extra-washing with ultrapure water, and then MTT, DNA quantification, mechanical tensile, and histological evaluations were performed. Results: Results showed that both R-ANGs and C-ANGs prepared by the OSD method had better biocompatibility, measured by MTT, than those prepared by the SD (p < 0.001). DNA quantification of samples obtained from the OSD method showed an improved elimination of residual DNA fragments (p < 0.0001). Mechanical tensile test also revealed a higher Young's modulus of the OSD grafts (p < 0.05). Histological studies, including hematoxylin and eosin, Masson's trichrome, Luxol fast blue, DAPI, and scanning electron microscopy (FESEM), confirmed that the OSD was superior to the SD in preserving ECM while equally removing cell nuclei and myelinated fibers. Conclusion: The OSD protocol yielded promising results for more reliable in vivo trials, as in vitro tests revealed better preservation of ECM components compared to the SD method. Notably, the OSD provided higher biocompatibility and improved viscoelastic integrity of the R-ANGs and C-ANGs.
Introduction: Given the sensory network dysfunction observed in migraine, this study aimed to investigate the effects of upper cervical mobilization on sensory brain activation using functional magnetic resonance imaging (fMRI) during trigeminal pain stimulation. Methods: Thirty-nine migraine patients were randomized into an intervention group (n = 22), receiving upper cervical mobilization, or a sham group (n = 17). All participants underwent fMRI scans before and after ten sessions. Trigeminal pain was induced using intranasal ammonia, and pain intensity was rated using the Visual Analog Scale (VAS). Brain activity was analyzed in sensory-related regions, including the primary somatosensory cortex (S1), angular and supramarginal gyri, superior parietal lobule (SPL), and thalamus. Outcomes included mean Z-score (statistical strength of brain activation relative to background noise), percent signal change (PSC; percentage change in regional BOLD signal relative to baseline), voxel count (activation volume), and contrast of parameter estimates (COPE; amplitude of the trigeminal pain-related BOLD response). using ANCOVA (adjusted for baseline), with effect sizes reported using epsilon squared (epsilon 2) or partial eta squared (eta 2). Results: The mobilization group showed a greater pain reduction (Cohen's d approximate to 2.60) than the sham group (r approximate to 0.64). Voxel count in bilateral supramarginal gyri decreased significantly (eta(2) approximate to 0.21, 0.11), as did BOLD signal in right SPL (epsilon(2) approximate to 0.08). Right S1 activation deviation correlated with pain reduction (r = 0.69). Pain reduction also correlated negatively with thalamic PSC (rho approximate to-0.36) and right angular gyrus COPD (rho approximate to-0.35). Conclusion: Upper cervical mobilization significantly reduced migraine pain and modulated activity in brain regions associated with pain and sensorimotor processing, suggesting a potential neurofunctional mechanism of action.
Introduction: Methylthiosemicarbazones (MTSCs) are compounds with various biological properties. Some studies have shown that their metal complexes have potential cytotoxic effects on numerous cancers. In this study, the effects of zinc (II)-methylthiosemicarbazone complex (Zn-MTC) on the human chronic myelogenous leukemia K562 cell line were evaluated. Methods: In this experimental study, K562 cells were treated with different doses of Zn-MTC for 24, 48, and 72 hours. We investigated whether this compound could induce cytotoxicity and apoptosis in K562 cells using the MTT assay, fluorescence microscopy, and flow cytometry. Results: Our findings indicated that Zn-MTC inhibited the growth of K562 cells and induced apoptosis in a time-and dose-dependent manner. The IC50 of the complex was 100 & micro;M after 72 hours of incubation. Morphological changes and sub-G1 cell cycle arrest confirmed the induction of apoptosis in K562 cells treated with the IC50 concentration of this compound. Conclusion: Given its antiproliferative and apoptosis-inducing effects, Zn-MTC can be proposed for further pharmaceutical evaluation in the treatment of chronic myeloid leukemia (CML) in the future.
Introduction: This research evaluates the treatment benefits of platelet-rich plasma (PRP) and erythropoietin (EPO) on diabetic nephropathy and hepatopathy in rats. Methods: Thirty male rats were separated into five groups: control, diabetic control, PRPtreated diabetic (1 mL PRP subcutaneously twice weekly), EPO-treated diabetic (300 units/ kg EPO subcutaneously three times weekly), and a combination of PRP and EPO treatment (1 mL PRP twice weekly and 300 units/kg EPO three times weekly). Diabetes was induced using streptozotocin (65 mg/kg), and treatments were administered over four weeks. Serum markers for renal and hepatic function, oxidative stress indices, and histopathological changes in liver and kidney tissues were assessed. Results: In diabetic rats, serum urea, creatinine, and liver enzymes (ALT, AST, ALP, LDH, GGT) increased significantly (p<0.05), while treatment with PRP, EPO, or both significantly reduced ALT, AST, ALP, LDH, and GGT (except in the combined group for GGT; p>0.05). Renal and hepatic SOD decreased significantly in diabetes (p<0.05) but improved with treatment, especially in the combined group (p<0.05). Renal TAC increased in diabetes and decreased significantly after treatment (p<0.05). No significant changes were observed in GPX or MDA levels (p>0.05). Damage in kidney and liver tissues were obtained in diabetic group. Histopathological improvements were evident, in hepatocyte integrity and glomerular structure, with EPO and PRP treatments. Conclusion: The results emphasize the potential of EPO and PRP as complementary therapeutic strategies to reduce diabetes-induced oxidative damage and structural deterioration in liver and kidney tissues. However, further adjunctive approaches are required to achieve comprehensive organ protection.